Day: January 24, 2022

Ageas and Ping An: Transparency notification In accordance with the rules on financial transparency*, Ping An has notified Ageas on 21 January 2022 that, on 19 January 2022, its interest has fallen below the statutory threshold of 3% of the shares issued by Ageas. Its current shareholding stands at 0%. Reason for the notification Acquisition or disposal of voting securities or voting rightsDownward crossing of the lowest threshold Notification by A parent undertaking or a controlling person Persons subject to the notification requirementSee annex 1a Date on which the threshold is crossed 19 January 2022 Threshold that is crossed (in %) 3% Denominator 191,033,128 Notified details See annex 1 b Chain of controlled undertakings through which the holding is effectively held, if applicable The full chain of command can be found on https://www.ageas.com/investors/shareholders This...

Basel, Switzerland, January 24, 2022 Basilea Pharmaceutica Ltd. (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with cancer and infectious diseases, announced today that updated interim results from cohort 2 of the phase 2 study FIDES-01 (Fibroblast growth factor Inhibition with DErazantinib in Solid tumors) were presented at the American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium 2022, held from January 20 to 22, in San Francisco, USA. Cohort 2 of FIDES-01 is assessing the safety and anti-tumor activity of Basilea’s orally administered fibroblast growth factor receptor (FGFR) inhibitor, derazantinib, in patients with locally advanced or metastatic intrahepatic cholangiocarcinoma (iCCA), a form of bile duct cancer, harboring FGFR2 mutations or amplifications.1 At...

January 24, 2022 Fourth-quarter highlightsGroup sales amounted to EUR 4.9 billion, with a 10% comparable sales decline Comparable order intake increased 4%, driven by double-digit growth in the Diagnosis & Treatment businesses Income from continuing operations amounted to EUR 139 million and included an impact of EUR 220 million related to the addition to the Respironics field action provision; income from continuing operations was EUR 508 million in Q4 2020 Adjusted EBITA of EUR 647 million, or 13.1% of sales, compared to EUR 995 million, or 19.0% of sales, in Q4 2020 Operating cash flow was EUR 720 million, resulting in a free cash flow of EUR 519 millionFull-year highlightsGroup sales amounted to EUR 17.2 billion, with high-single-digit comparable sales growth in the Diagnosis & Treatment and Personal Health businesses,...

WISeKey to Participate at the Blockchain Conference “Trends in the World of NFTs and Crypto” Presented by Maxim Group and Hosted by M-Vest on January 27 Geneva – January 24, 2022 – WISeKey International Holding Ltd. (“WISeKey,” SIX: WIHN / Nasdaq: WKEY), a leading global Semi-conductor, AI and IoT company, today announced that its CEO, Carlos Moreira is scheduled to participate in two panel discussions at the Blockchain Conference “Trends in the World of NFTs and Crypto” presented by Maxim Group LLC and hosted by M-Vest, on Thursday, January 27, starting at 12:00 noon ET (6:00 pm CET). Conference agenda and registration details can be found at https://m-vest.com/events/2022-blockchain-conference. Specifically, Mr. Moreira will participate in the following panel discussions:12:00 noon ET: Go to market strategies panel –...

Ad hoc announcement pursuant to Art. 53 LR Idorsia appoints Guy Braunstein to Chief Medical Officer and Alberto Gimona to Head of Global Clinical DevelopmentGuy Braunstein, currently Head of Global Clinical Development, to assume newly created role of Chief Medical Officer and remain a member of the Idorsia Executive Committee Alberto Gimona, currently Head of Therapeutic Area Units, to succeed Guy Braunstein and join the Idorsia Executive CommitteeAllschwil, Switzerland – January 24, 2022Idorsia Ltd (SIX: IDIA) today announced the appointment of Guy Braunstein, who has served as Head, Global Clinical Development since the creation of Idorsia and before, since 2009 at Actelion, to a newly created role – Chief Medical Officer (CMO) and affirms that Guy will continue to serve as a member of the Idorsia Executive Committee (IEC) in this...

AES Technology inventor, Pinakin Patel, elected to the California Hydrogen Business Council (CHBC) Board The CHBC is a prestigious group advocating hydrogen policy at a national level promoting commercialization of new and existing technologies Mr. Patel’s appointment will ensure AES technology meets the needs of the United States transition to low-carbon economy, marking another step towards the successful adoption and commercialization of AES technologyTORONTO, Jan. 24, 2022 (GLOBE NEWSWIRE) — PowerTap Hydrogen Capital Corp (NEO: MOVE) (FWB: 2K6B) (OTC: MOTNF) (“PowerTap” or the “Company” or “MOVE”) is pleased to announce that Pinakin Patel, co-founder of AES-100 Inc, and lead inventor of the Advance Electrolyzer Technology (AES) for green hydrogen technology, has been elected to the CHBC Board. The California Hydrogen Business...

AES Technology inventor, Pinakin Patel, elected to the California Hydrogen Business Council (CHBC) Board The CHBC is a prestigious group advocating for hydrogen policy at a national level promoting commercialization of new and existing technologies Pinakin’s appointment better positions AES to meet the needs of the United States transition to a low-carbon economyTORONTO, Jan. 24, 2022 (GLOBE NEWSWIRE) — Aberdeen International Inc. (“Aberdeen” or the “Company”) (TSX: AAB F: A8H, OTC: AABVF) is pleased to announce that Pinakin Patel, co-founder of AES-100 Inc, and lead inventor of the Advance Electrolyzer System technology (AES) for green hydrogen production, has been elected to the California Hydrogen Business Council (‘CHBC’) Board. The CHBC is a national organization promoting and advocating for the commercialization...

MCH Group participates in new art fair in Singapore MCH Swiss Exhibition (Basel) Ltd., a company of MCH Group Ltd. based in Basel/Switzerland, is taking a 15% stake as shareholder in Arts Events Singapore Pte. Ltd., the organizer of the new art fair ART SG in Singapore. Arts Events Singapore Pte. Ltd. and ART SG are owned by the exhibition companies of Sandy Angus, Tim Etchells and Magnus Renfrew, who are well known in the international art market. ART SG will be launched at the Marina Bay Sands Expo and Convention Centre on 12-15 January 2023, and is expected to become a leading contemporary art fair in Southeast Asia with around 100 galleries. “By participating in ART SG, we want to contribute to the further development of the art market in Southeast Asia and strengthen our position in this geographical area,” says Beat...